Publications 2021

Andersen AM, Bergan S, Gedde-Dahl T, Buechner J, Vethe NT (2021)
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J. Pharm. Biomed. Anal., 203, 114216
DOI 10.1016/j.jpba.2021.114216

Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S et al. (2021)
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther. Drug Monit., 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871

Brede C, Vethe NT, Skadberg O (2021)
The Question of Accuracy Versus Interlaboratory Agreement for Monitoring the Immunosuppressants Everolimus and Sirolimus
Ther. Drug Monit., 43 (3), 444-446
DOI 10.1097/FTD.0000000000000892

Kindem IA, Bjerre A, Asberg A, Midtvedt K, Bergan S, Vethe NT (2021)
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther. Drug Monit., 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873

Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, Perk J, Dammen T, Husebye E, Vethe NT, Munkhaugen J (2021)
The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
Atherosclerosis, 336, 23-29
DOI 10.1016/j.atherosclerosis.2021.09.020

Kristiansen O, Vethe NT, Peersen K, Fagerland MW, Sverre E, Jensen EP, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J (2021)
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
EUR. HEART J.-CARDIOVASC. PHARMACOTHER., 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076

Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, Perk J, Husebye E, Dammen T (2021)
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects
BMC Cardiovasc. Disord., 21 (1), 596
DOI 10.1186/s12872-021-02422-7

Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H (2021)
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin. Pharmacol. Toxicol., 129 (6), 427-436
DOI 10.1111/bcpt.13645

Skauby RH, Gustavsen MT, Andersen AM, Bjerre A, Asberg A, Midtvedt K, Vethe NT, Bergan S (2021)
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther. Drug Monit., 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835

Publications 2020

Amrutkar M, Vethe NT, Verbeke CS, Aasrum M, Finstadsveen AV, Santha P, Gladhaug IP (2020)
Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing
Cancers, 12 (12), 3628
DOI 10.3390/cancers12123628

Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Asberg A (2020)
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
CTS-Clin. Transl. Sci., 13 (6), 1327-1335
DOI 10.1111/cts.12833

Gustavsen MT, Midtvedt K, Vethe NT, Robertsen I, Bergan S, Asberg A (2020)
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther. Drug Monit., 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697

Klaasen RA, Bergan S, Bremer S, Hole K, Nordahl CB, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2020)
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br. J. Clin. Pharmacol., 86 (6), 1100-1112
DOI 10.1111/bcp.14218

Kvamsoe MM, Hansen KR, Skadberg O, Vethe NT, Brede C (2020)
Salting Out-Assisted Liquid-Liquid Extraction for Liquid Chromatography-Tandem Mass Spectrometry Measurement of Tacrolimus, Sirolimus, Everolimus, and Cyclosporine a in Whole Blood
Ther. Drug Monit., 42 (5), 695-701
DOI 10.1097/FTD.0000000000000794

Lemaitre F, Vethe NT, D'Avolio A, Tron C, Robertsen I, De Winter B, Denicolo A, Koch BCP, Venkataramanan R, Van Gelder T, Brunet M, Bergan S, Hesselink DA, Wallemacq P (2020)
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther. Drug Monit., 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780

Publications 2019

Bergstrom M, Muller M, Karlsson M, Scholz H, Vethe NT, Korsgren O (2019)
Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
Cell Transplant., 28 (12), 0963689719872488-1613
DOI 10.1177/0963689719872488

Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millan O et al. (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther. Drug Monit., 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640

Kristiansen O, Vethe NT, Fagerland MW, Bergan S, Munkhaugen J, Husebye E (2019)
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br. J. Clin. Pharmacol., 85 (12), 2878-2885
DOI 10.1111/bcp.14122

Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernaes KH, Vethe NT, Prescott E, Jensen SE, Rodevand O, Jortveit J, Bendz B, Schirmer H, Kober L, Botker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, Atar D (2019)
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am. Heart J., 208, 37-46
DOI 10.1016/j.ahj.2018.10.005

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand. Cardiovasc. J., 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085

Tuv SS, Vethe NT, Bergan S, Nordal K (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702

Vethe NT, Gustavsen MT, Midtvedt K, Lauritsen ME, Andersen AM, Asberg A, Bergan S (2019)
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther. Drug Monit., 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655

Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019)
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther. Drug Monit., 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578

Publications 2018

Klaasen RA, Bergan S, Bremer S, Daleq L, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2018)
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther. Drug Monit., 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539

Krogstad V, Vethe NT, Robertsen I, Hasvold G, Ose AMD, Hermann M, Andersen AM, Chan J, Skauby M, Svensson MHS, Asberg A, Christensen H (2018)
Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies
Ther. Drug Monit., 40 (3), 292-300
DOI 10.1097/FTD.0000000000000510

Publications 2017

Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S (2017)
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br. J. Clin. Pharmacol., 83 (11), 2494-2502
DOI 10.1111/bcp.13367

Skauby RH, Bjerre A, Saeves I, Vethe NT, Bremer S, Svarstad A, Bergan S (2017)
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther. Drug Monit., 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439

Publications 2016

Bergan S, Bremer S, Vethe NT (2016)
Drug target molecules to guide immunosuppression
Clin. Biochem., 49 (4-5), 411-418
DOI 10.1016/j.clinbiochem.2015.10.001

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J. Diabetes Res., 2016, 4196460
DOI 10.1155/2016/4196460

Publications 2015

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets invitro
Transpl. Int., 28 (10), 1152-1161
DOI 10.1111/tri.12617

Robertsen I, Asberg A, Ingero AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of Generic Tacrolimus in Elderly Renal Transplant Recipients Precaution Is Needed
Transplantation, 99 (3), 528-532
DOI 10.1097/TP.0000000000000384

Robertsen I, Vethe NT, Midtvedt K, Falck P, Christensen H, Asberg A (2015)
Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations
Ther. Drug Monit., 37 (5), 675-680
DOI 10.1097/FTD.0000000000000185

Publications 2014

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K (2014)
More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
Transplantation, 97 (12), 1266-1271
DOI 10.1097/01.TP.0000443225.66960.7e

Saeves I, Line PD, Bremer S, Vethe NT, Tveit RG, Meltevik TJ, Bergan S (2014)
Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation
Ther. Drug Monit., 36 (1), 46-53

Vethe NT, Ali AM, Reine PA, Andersen AM, Bremer S, Line PD, Rootwelt H, Bergan S (2014)
Simultaneous Quantification of IMPDH Activity and Purine Bases in Lymphocytes Using LC-MS/MS: Assessment of Biomarker Responses to Mycophenolic Acid
Ther. Drug Monit., 36 (1), 108-118

Publications 2013

Reine PA, Vethe NT, Kongsgaard UE, Andersen AM, Line PD, Ali AM, Bergan S (2013)
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand. J. Clin. Lab. Invest., 73 (2), 117-124
DOI 10.3109/00365513.2012.745947

Publications 2011

Midtvedt K, Jenssen T, Hartmann A, Vethe NT, Bergan S, Havnes K, Asberg A (2011)
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol. Dial. Transplant., 26 (11), 3767-3772
DOI 10.1093/ndt/gfr153

Saeves I, Vethe NT, Bergan S (2011)
Quantification of 6 Glucocorticoids in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry: Method Development, Validation, and Assessment of Matrix Effects
Ther. Drug Monit., 33 (4), 402-410
DOI 10.1097/FTD.0b013e3182241799

Publications 2010

Vethe NT, Gjerdalen LC, Bergan S (2010)
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: Assessment of matrix effects and assay performance
Scand. J. Clin. Lab. Invest., 70 (8), 583-591
DOI 10.3109/00365513.2010.531141

Publications 2009

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K (2009)
Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients
Transplantation, 87 (8), 1221-1224
DOI 10.1097/TP.0b013e31819f1001

Bremer S, Vethe NT, Rootwelt H, Bergan S (2009)
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int. Immunopharmacol., 9 (2), 173-180
DOI 10.1016/j.intimp.2008.10.017

Bremer S, Vethe NT, Rootwelt H, Jorgensen PF, Stenstrom J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J. Transl. Med., 7, 64
DOI 10.1186/1479-5876-7-64

Vethe NT (2009)
Molecular pharmacodynamics of the immunosuppressant mycophenolic acid: a basis for monitoring and individualized treatment
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 741, 1 b. (flere pag.)
BIBSYS 091766974, ISBN 978-82-8072-780-0

Publications 2008

Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S (2008)
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JLE, Holdaas H (2008)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol. Dial. Transplant., 23 (3), 1048-1053
DOI 10.1093/ndt/gfm632

Vethe NT, Bremer S, Bergan S (2008)
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand. J. Clin. Lab. Invest., 68 (4), 277-285
DOI 10.1080/00365510701724871

Vethe NT, Bremer S, Rootwelt H, Bergan S (2008)
Pharmacodynamics of Mycophenolic Acid in CD4(+) Cells: A Single-Dose Study of IMPDH and Purine Nucleotide Responses in Healthy Individuals
Ther. Drug Monit., 30 (6), 647-655
DOI 10.1097/FTD.0b013e31818955c3

Publications 2006

Vethe NT, Bergan S (2006)
Determination of inosine monophosphate dehydrogenase activity in human CD4+cells isolated from whole blood during mycophenolic acid therapy
Ther. Drug Monit., 28 (5), 608-613
DOI 10.1097/01.ftd.0000245680.38143.ca

Publications 2002

Vethe NT (2002)
Effekten av mykofenolat på IMP-dehydrogenase ved immunsuppressiv behandling av nyretransplanterte pasienter
N.T. Vethe, Oslo, 59, vi s.
BIBSYS 022449574